You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

343 Results
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
ODB - General Benefit
    capecitabine
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
ODB - General Benefit
    capecitabine
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
ODB - General Benefit
    filgrastim (biosimilars) - refer to ODB Formulary for details
Nov 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    capivasertib - For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, based on criteria
ODB - General Benefit
    fulvestrant
Oct 2025

Pages